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COMMENTARY
NAFLD Phenotype in Patients
With V-ATPase Proton Pump
Assembly Defects
Nonalcoholic fatty liver disease (NAFLD) is a verycommon chronic liver disease marked by hepatic
fat accumulation. This might trigger inﬂammation and
liver cell injury, a condition known as nonalcoholic
steatohepatitis. Nonalcoholic steatohepatitis may promote
ﬁbrogenesis and evolve toward cirrhosis and hepatocel-
lular carcinoma, and is considered the phenotypic
extension of NAFLD.
There is considerable heterogeneity in NAFLD.
Most patients carry several features of the metabolic
syndrome such as insulin resistance. However, there
are well-documented NAFLD cases without metabolic
syndrome. For these cases of secondary NAFLD, the
mechanism of steatogenesis appears to be independent of
insulin resistance and adipose tissue expansion. Second-
ary causes of NAFLD are important to recognize because
their natural history, associated symptoms, and
overall management differ from that of metabolic
syndrome–associated NAFLD. Known inborn errors of
metabolism that cause NAFLD are hypo- or abetalipo-
proteinemia, lysosomal acid lipase deﬁciency, and
Wilson disease.1
Lesser-known inborn errors of metabolism that can
cause liver injury are primary glycosylation defects or
congenital disorders of glycosylation (CDGs). Glycosylation
is the attachment of a glycan, composed of monosaccharides,
to a protein or lipid and is a complex and highly regulated
form of post-translational modiﬁcation.2 The process starts
in the endoplasmic reticulum (ER), where the glycan buildup
and en bloc transfer to the nascent protein or lipid take
place. If correctly folded, the newly formed glycoprotein
travels to the Golgi apparatus (or simply Golgi). In the Golgi,
modiﬁcation of the glycan takes place, which results in the
mature glycoprotein, ready to be transported to other
cellular compartments or secreted into the bloodstream.3
To date, more than 100 CDGs have been discovered and
this number is expanding rapidly.4 The majority of defects
are inherited in an (X-linked) autosomal-recessive pattern
and the group as a whole presents a complex heterogeneous
phenotype. As the main site for protein synthesis, the liver
frequently is affected in CDG and increased aspartate
aminotransferase and alanine aminotransferase serum
levels are a common ﬁnding.5
Recently, we identiﬁed 3 novel CDG subtypes in 23
patients, ranging from neonates to adults, from 14 families
across Europe. Patients with mutations in TMEM199 (MIM:
616829), CCDC115 (MIM: 616828), and ATP6AP1 (MIM:
300972) presented with a NAFLD phenotype including
steatosis on liver biopsy and increased liver enzymes.6–8
Low serum ceruloplasmin and increased hepatic copper
concentrations were present in selected patients, without
meeting the Wilson disease criteria. Nonhepatic symptoms
such as hypercholesterolemia (for all defects), neurode-
generative symptoms (CCDC115 and ATP6AP1 deﬁciency),
and hypogammaglobulinemia (ATP6AP1 deﬁciency) are
also present. Various other nonhepatic symptoms can be
found (Supplementary Table 1). The families were identiﬁed
based on their abnormal protein glycosylation pattern
through a straightforward biochemical assay. The severity
of symptoms varied: some patients had isolated mild
increases of transaminase levels whereas others developed
end-stage liver disease necessitating liver transplantation.
TMEM199, CCDC115, and ATP6AP1 most likely function
in the assembly of the vacuolar Hþ adenosine triphospha-
tase, or V-ATPase. The V-ATPase is the main proton pump
of the secretory pathway for acidiﬁcation of the Golgi and
lysosomes. It also is involved in a large number of addi-
tional cellular functions such as protein trafﬁcking and
membrane fusion.9 The V-ATPase consists of 14 core units
divided between 2 domains: a transmembrane V0 domain
and a cytosolic V1 domain. The V1 domain provides the
energy for the V0 domain to translocate protons. The V0
domain consists of a proteolipid ring (made from c, c’, and
c’’ subunits) and a cage structure made from subunit a.
An additional d subunit provides the link between the
V0 and V1 domains.
TMEM199 and CCDC115 are located in the ER-to-Golgi
intermediate complex (ERGIC), and in coatomer protein
complex I and II (COPI and COPII) vesicles in HeLa- and
primary hepatoma cells.7,8 TMEM199, 208–amino acids
small, is a transmembrane protein and shares a Vma12
domain that is conserved throughout species. CCDC115 is a
181–amino acid small protein with 2 coiled-coil domains. A
recent immunoprecipitation study and large proteome-wide
interaction studies have shown an interaction of TMEM199
with CCDC115.10,11 ATP6AP1 is located on the X chromo-
some and encodes the 470–amino acid long Ac45 protein.
Ac45 is a V-ATPase accessory protein and is located in the
ER and ERGIC. In yeast, it interacts with the c’’ subunit of the
proteolipid ring of the V-ATPase complex.12
Mutations in all 3 proteins lead to impaired N- and
O-glycosylation with a pattern compatible with defects in
Golgi homeostasis. Impaired expression of TMEM199,
CCDC115, and ATP6AP1 likely results in impaired func-
tioning of the lysosomal compartment, similar to knock-
down of the V-ATPase.11,12
Yeast studies with homologs of TMEM199, CCDC115,
and ATP6AP1 have shown that during assembly of the V0
domain, Vph2p (yeast homolog of TMEM199) and Vma22p
(homolog of CCDC115) stabilize the cage structure. Voa1p
(homolog of ATP6AP1) and Vma21p (homolog of VMA21, a
fourth protein) stabilize the proteolipid ring and chaperone
the V0 domain from the ER to the Golgi.9
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These data lead to a model that places these proteins in
the assembly pathway of the V-ATPase V0 domain. CCDC115
and TMEM199 stabilize the a-subunit during assembly and
VMA21 and cleaved Ac45 stabilize the c-ring and guide the
V0 domain (or the holocomplex with the V1 domain) to the
Golgi. VMA21, and possibly CCDC115 and TMEM199, then
are transported back via COPI vesicles. However, this model
largely is based on yeast studies, and functional evidence in
human beings for involvement of CCDC115 and TMEM199
in ER-to-Golgi transport currently is lacking.
Our hypothesis is that defects in V-ATPase assembly
factors lead to abnormal glycosylation because they impair
ER-to-Golgi protein trafﬁcking. Indeed, V-ATPase assembly
factors co-localize with COPI, COPII, and ERGIC markers,
indicating a function in early protein transport. In addition,
serum proteins from patients with a V-ATPase assembly
factor defect have a speciﬁc glycosylation pattern, indicative
for abnormal Golgi protein trafﬁcking.
Impaired protein trafﬁcking also could explain the
NAFLD phenotype because emerging insights in ER-to-lipid
droplet protein trafﬁcking show that knockdown of the
COPI machinery results in intracellular triglyceride accu-
mulation.13 However, further research is required to
establish if the phenotype is dependent on defects in the
V-ATPase assembly proteins, the function of the V-ATPase,
impaired glycosylation, or a factor yet undetermined.
To conclude, V-ATPase assembly protein deﬁciencies are a
novel group of inborn errors of metabolism that have to be
considered in the differential diagnosis of NAFLD not associ-
ated with the metabolic syndrome. The hepatic phenotype
ranges from mild impairment to end-stage liver disease
necessitating liver transplantation. We propose a multifaceted
etiology based on abnormal Golgi apparatus homeostasis.
Screening can be performed easily via glycosylation analytics.
Better awareness of these genetic defects will improve patient
outcome and provide new insights in the etiology of NAFLD.
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Supplementary Table 1.Extrahepatic Symptoms of V-ATPase Assembly Factor Deﬁciencies
Extrahepatic symptoms TMEM199-CDG CCDC115-CDG ATP6AP1-CDG
Dysmorphic facial features - þ -
Psychomotor disability ± þ ±
Neurologic symptoms
Hypotonia ± þ ±
Seizures - - ±
Sensineural hearing loss - - þ
Hematologic symptoms
Abnormal coagulation factors ± ± NA
Anemia NA ± NA
Leukopenia NA NA þ
Hypogammaglobulinemia - - þ
Creatine kinase NA NA ±
Splenomegaly - þ þ
Hypoglycemia NA ± NA
Hypercholesterolemia þ þ NA
Bone anomalies - - -
A G A A C C G G A G T C C
T C T T G G C C T C A G G
a
c’’cc
d
1. autosomal recessive inheritance
2. defective protonpump assembly
3. abnormal protein glycosylation
+NAFLD glycosylation defectsadditional symptoms →
CNS
all patients
↑ ALT, AST
↑ alk. phos
↑ cholesterol 
↓ ceruloplasmin
selected patients
seizures
failure to thrive
psychomotor 
retardation
Supplemental Graphical Summary.
417.e1 Commentary Cellular and Molecular Gastroenterology and Hepatology Vol. 5, No. 3
